Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25430011 | 0.87 | TTBK1 (0.41) | ELANEPDE10AADORA2AADORA1AURKB | |
| SCHEMBL25430881 | 0.80 | PDE10A (0.42) | ELANEPDE10A | |
| SCHEMBL25430936 | 0.73 | GSK3B (0.35) | ELANEPDE10AAURKBAURKATPX2 | |
| SCHEMBL25430366 | 0.72 | TTBK1 (0.42) | ADORA2AADORA1 | |
| SCHEMBL25431453 | 0.67 | FEN1 (0.40) | PDE10A | |
| SCHEMBL25380655 | 0.67 | FEN1 (0.46) | PDE10A | |
| SCHEMBL20406094 | 0.67 | PDE10A (0.45) | PDE10A | |
| SCHEMBL30482538 | 0.67 | PDE10A (0.45) | PDE10A | |
| SCHEMBL25339739 | 0.67 | DRD1 (0.43) | PDE10A | |
| SCHEMBL25341778 | 0.65 | PDE10A (0.47) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |